[{"id":"6684d102-d547-464e-a149-25b339d38698","acronym":"","url":"https://clinicaltrials.gov/study/NCT03319459","created_at":"2021-01-18T16:23:34.983Z","updated_at":"2024-07-02T16:36:20.361Z","phase":"Phase 1","brief_title":"FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03319459","lead_sponsor":"Fate Therapeutics","biomarkers":" EGFR • HER-2","pipe":"","alterations":" ","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • FATE-NK100"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 01/18/2018","start_date":" 01/18/2018","primary_txt":" Primary completion: 05/29/2020","primary_completion_date":" 05/29/2020","study_txt":" Completion: 12/15/2020","study_completion_date":" 12/15/2020","last_update_posted":"2021-11-22"}]